Cortechs.ai Expands NeuroQuant® to Revolutionize Brain Tumor Imaging with AI
Cortechs.ai, a leader in artificial intelligence for medical imaging, has announced a major enhancement to its FDA-cleared NeuroQuant® Brain Tumor software. The latest version introduces fully automated segmentation and volumetric reporting for brain metastases and meningiomas, expanding the platform’s capabilities beyond its existing focus on gliomas.
NeuroQuant® Brain Tumor is a post-processing software designed to support radiologists, neuro-oncologists, neurosurgeons, and other clinicians in interpreting brain MRI scans. By automatically segmenting and quantifying tumor volumes, the software provides a more objective and consistent approach to analyzing brain tumors with confirmed pathological diagnoses.
The newly added AI models for brain metastases and meningiomas complement the platform’s existing support for high- and low-grade gliomas. These additions are now available through Cortechs.ai’s secure cloud-based platform, which allows for seamless integration into Picture Archiving and Communication Systems (PACS) and scalable deployment across healthcare networks.
According to the company, this technological advancement is designed to save clinicians time, reduce variability in interpretations, and improve diagnostic confidence. By providing longitudinal tracking of tumor changes, the software enables more precise monitoring of treatment response and disease progression.
“NeuroQuant® Brain Tumor’s longitudinal tracking capabilities offer critical insights into changes in tumor volume over time,” said Dr. Nikdokht Farid, a neuroradiologist at UC San Diego. “With the latest software release, which offers automated segmentation and tracking of brain metastases and meningiomas, this tool has tremendous potential to improve workflow efficiency and clinical confidence in detecting, measuring, and following these tumors.”
Another key innovation in this release is its integration into radiation oncology and neurosurgical workflows. Clinicians can now import segmentation results directly into treatment planning systems, streamlining the process and eliminating the need for manual contouring. This not only enhances efficiency but also improves collaboration between departments.
“This isn’t just another tool—it’s a powerful engine that empowers healthcare professionals with advanced capabilities they’ve never had before,” said Kyle Frye, CEO of Cortechs.ai. “We are continuing to bring together the continuum of care with radiology, surgery, and oncology with our latest version of NeuroQuant® Brain Tumor.”
Nate White, CTO of Cortechs.ai, added, “Our technology transforms hours of manual work into minutes of precise, automated analysis. This isn't just about efficiency—it’s about equipping clinicians with the tools and insights they need to deliver better patient care while streamlining workflows in increasingly strained healthcare systems.”
As the first FDA-cleared, cloud-native tool to automate volumetric segmentation for both brain metastases and meningiomas, NeuroQuant® Brain Tumor continues to set a new standard for AI in neuroimaging. By building on its track record in glioma tracking and structural brain volumetrics, the platform now offers a unified, scalable solution for routine clinical use.
This milestone not only enhances diagnostic and planning capabilities but also supports a broader vision of integrated, AI-powered care—bridging radiology, neurosurgery, and oncology to improve outcomes for patients with complex brain tumors.